Josep Maria Piulats
Overview
Explore the profile of Josep Maria Piulats including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varela M, Villatoro S, Lorenzo D, Piulats J, Caminal J
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272911
Uveal melanoma (UM) is the most common primary malignant intraocular tumor in adults. Distant metastasis is common, affecting around 50% of patients. Prognostic accuracy relies on molecular characterization of tumor...
2.
Martin-Liberal J, Garralda E, Garcia-Donas J, Soto-Castillo J, Mussetti A, Codony C, et al.
Future Oncol
. 2024 Aug;
20(32):2437-2445.
PMID: 39129675
The SWI/SNF complex is a chromatin remodeling complex comprised by several proteins such as SMARCA4 or SMARCB1. Mutations in its components can lead to the development of aggressive rhabdoid tumors...
3.
Garcia-Mulero S, Fornelino R, Punta M, Lise S, Varela M, Del Carpio L, et al.
Oncoimmunology
. 2023 Dec;
12(1):2261278.
PMID: 38126027
Uveal melanoma (UM) is the most common ocular malignancy in adults. Nearly 95% of UM patients carry the mutually exclusive mutations in the homologous genes (amino acid change Q209L/Q209P) and...
4.
Plaja A, Teruel I, Ochoa-de-Olza M, Cucurull M, Arroyo A, Pardo B, et al.
Int J Mol Sci
. 2023 Jul;
24(14).
PMID: 37511180
Despite a multimodal radical treatment, mortality of advanced epithelial ovarian cancer (AEOC) remains high. Host-related factors, such as systemic inflammatory response and its interplay with the immune system, remain underexplored....
5.
Lozano-Rabella M, Garcia-Garijo A, Palomero J, Yuste-Estevanez A, Erhard F, Farriol-Duran R, et al.
Clin Cancer Res
. 2023 Feb;
29(12):2250-2265.
PMID: 36749875
Purpose: Tumor antigens are central to antitumor immunity. Recent evidence suggests that peptides from noncanonical (nonC) aberrantly translated proteins can be presented on HLA-I by tumor cells. Here, we investigated...
6.
Palomero J, Panisello C, Lozano-Rabella M, Tirtakasuma R, Diaz-Gomez J, Grases D, et al.
J Immunother Cancer
. 2022 Dec;
10(12).
PMID: 36581331
Background: Despite the growing interest in immunotherapeutic interventions for endometrial cancer (EC), the prevalence, phenotype, specificity and prognostic value of tumor infiltrating lymphocytes (TILs) in this tumor type remains unclear....
7.
Caminal J, Lorenzo D, Gutierrez C, Slocker A, Piulats J, Cobos E, et al.
J Clin Med
. 2022 Dec;
11(23).
PMID: 36498730
Surgical resection is widely used to treat small tumours located in the iris and the ciliary body, due to the accessibility of these sites. By contrast, surgical removal of choroidal...
8.
Alonso-Maranon J, Villanueva A, Piulats J, Martinez-Iniesta M, Sole L, Martin-Liberal J, et al.
Oncogene
. 2021 Jun;
40(31):5042-5048.
PMID: 34140639
Invasive malignant melanoma (MM) is an aggressive tumor with no curative therapy in advanced stages. Chemotherapy has not demonstrated its efficacy in MM and current treatment for tumors carrying the...
9.
Rodriguez-Martinez A, Trapero C, Vidal A, Piulats J, Gomez de Aranda I, Sevigny J, et al.
J Pers Med
. 2021 Apr;
11(5).
PMID: 33922226
Ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2/CD39L1) has been described in human non-pathological endometrium in both epithelial and stromal components without changes along the cycle. It was identified as a stromal marker of...
10.
Espana S, Ochoa de Olza M, Sala N, Piulats J, Ferrandiz U, Etxaniz O, et al.
Cancer Manag Res
. 2020 Oct;
12:10251-10260.
PMID: 33116879
Background: Abiraterone acetate (AA) is widely used in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). However, a significant percentage of patients will still progress, highlighting the need...